I liked this line:
Quote:
|
Women with HER2 +3 who were administered trastuzumab as part of the standard of care prior to receiving the vaccine experienced no cases of cancer recurrence.
|
So ladies, are we looking at high cure rates with these vaccines? It appears so. Not only the early stage Her2 3+ with GP2, but the subset of triple negative with low Her2 expression might also reach high cure rates with the E75. I expect good news from AE37 as well.
We lucky ladies who entered these trials need to stay in touch with the trial administrators. I personally would like to see data beyond 5 years.